Bank of New York Mellon’s Avidity Biosciences RNA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $10.9M | Buy |
383,160
+16,566
| +5% | +$470K | ﹤0.01% | 1850 |
|
|
2025
Q1 | $10.8M | Buy |
366,594
+3,577
| +1% | +$106K | ﹤0.01% | 1814 |
|
|
2024
Q4 | $10.6M | Buy |
363,017
+59,295
| +20% | +$1.72M | ﹤0.01% | 1897 |
|
|
2024
Q3 | $13.9M | Sell |
303,722
-60,231
| -17% | -$2.77M | ﹤0.01% | 1767 |
|
|
2024
Q2 | $14.9M | Buy |
363,953
+115,676
| +47% | +$4.73M | ﹤0.01% | 1745 |
|
|
2024
Q1 | $6.34M | Sell |
248,277
-10,371
| -4% | -$265K | ﹤0.01% | 2199 |
|
|
2023
Q4 | $2.34M | Buy |
258,648
+6,616
| +3% | +$59.9K | ﹤0.01% | 2746 |
|
|
2023
Q3 | $1.61M | Sell |
252,032
-2,395
| -0.9% | -$15.3K | ﹤0.01% | 2926 |
|
|
2023
Q2 | $2.82M | Buy |
254,427
+22,779
| +10% | +$253K | ﹤0.01% | 2644 |
|
|
2023
Q1 | $3.56M | Buy |
231,648
+35,555
| +18% | +$546K | ﹤0.01% | 2485 |
|
|
2022
Q4 | $4.35M | Buy |
196,093
+20,293
| +12% | +$450K | ﹤0.01% | 2415 |
|
|
2022
Q3 | $2.87M | Buy |
175,800
+19,046
| +12% | +$311K | ﹤0.01% | 2611 |
|
|
2022
Q2 | $2.28M | Buy |
156,754
+20,133
| +15% | +$292K | ﹤0.01% | 2758 |
|
|
2022
Q1 | $2.52M | Buy |
136,621
+719
| +0.5% | +$13.3K | ﹤0.01% | 2808 |
|
|
2021
Q4 | $3.23M | Buy |
135,902
+15,409
| +13% | +$366K | ﹤0.01% | 2703 |
|
|
2021
Q3 | $2.97M | Buy |
120,493
+26,077
| +28% | +$642K | ﹤0.01% | 2769 |
|
|
2021
Q2 | $2.33M | Buy |
94,416
+9,965
| +12% | +$246K | ﹤0.01% | 2892 |
|
|
2021
Q1 | $1.84M | Buy |
84,451
+21,177
| +33% | +$462K | ﹤0.01% | 2965 |
|
|
2020
Q4 | $1.62M | Buy |
63,274
+16,639
| +36% | +$425K | ﹤0.01% | 2966 |
|
|
2020
Q3 | $1.31M | Buy |
+46,635
| New | +$1.31M | ﹤0.01% | 2951 |
|